Twenty-Four-Month Blood Pressure Results After Renal Denervation Using Endovascular Ultrasound

BACKGROUNDRenal denervation has proven its efficacy to lower blood pressure in comparison to sham treatment in recent randomized clinical trials. Although there is a large body of evidence for the durability and safety of radiofrequency-based renal denervation, there are a paucity of data for endovascular ultrasound-based renal denervation (uRDN). We aimed to assess the long-term efficacy and safety of uRDN in a single-center cohort of patients. METHODS AND RESULTSData from 2 previous studies on uRDN were pooled. Ambulatory 24-hour blood pressure measurements were taken before as well as 3, 6, 12, and 24 months after treatment with uRDN. A total of 130 patients (mean age 63 & PLUSMN;9 years, 24% women) underwent uRDN. After 3, 6, 12, and 24 months, systolic mean 24-hour ambulatory blood pressure values were reduced by 10 & PLUSMN;12, 10 & PLUSMN;14, 8 & PLUSMN;15, and 10 & PLUSMN;15 mm Hg, respectively, when compared with baseline (P<0.001). Corresponding diastolic values were reduced by 6 & PLUSMN;8, 6 & PLUSMN;8, 5 & PLUSMN;9, and 6 & PLUSMN;9 mm Hg, respectively (P<0.001). Periprocedural adverse events occurred in 16 patients, and all recovered without sequelae. CONCLUSIONSIn this single-center study, uRDN effectively lowered blood pressure up to 24 months after treatment.

Automated summary

This study pooled data from two previous studies on endovascular ultrasound-based renal denervation (uRDN) and found that uRDN effectively lowered blood pressure for up to 24 months after treatment, with low rates of adverse events.